Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836

US: +1-800-914-7836

Make An Inquiry
What's new

Latest news

Home Page 25

Invitation Letter for Current Pharmaceutical Design

Current Pharmaceutical Design

Dr. A. S. Srivastava                                                                                                                                                                                                                                                                               

Stem Cell Core Labratory
Salk Institute for Biological Studies La Jolla
CA 92037
United States

Dear Dr. Srivastava,

On behalf of the editorial board of “Current Pharmaceutical Design”, I would like to propose your name to be considered as an Executive Guest Editor for a thematic issue of the journal in a hot topic area.

“Current Pharmaceutical Design” is a leading international journal, which publishes frontier reviews in important fields of drug discovery. The journal is published by Bentham Science Publishers and has been widely acclaimed because of its excellent standards and the high quality of publications. It is abstracted/indexed in a number of major abstracting/indexing agencies, Impact Factor: 6.452 (2014 SCI Journal Citation Reports). Each issue is published under a Guest Editor who is an authority in the field and who is responsible for soliciting top class articles covering various important aspects of the field from leading authorities.

Bentham Science Publishers is currently publishing 42 issues of the journal annually. These “theme issues” contain articles in important fields of current research activity written by eminent experts in the field. The Guest Editor is responsible for soliciting top class articles covering various important aspects of the selected topic from leading authorities in the field. In view of current demand for the journal, the publishers are soliciting additional topic themes relevant to pharmaceutical design. Please visit the website of Current Pharmaceutical Design for more information.

If you are interested in being considered for the post of Executive Guest Editor, then please send us the following:

1. Title of your topic or theme.
2. List of authors (along with their affiliation) and the titles of the articles they are contributing.
3. Brief introduction of the issue.
4. A description stating how the subject will contribute to the field.
5. Your complete CV and detailed list of publications.

The aim of the journal is to provide readers with comprehensive accounts of recent developments in the frontier areas of the field. The articles should take the form of full-length manuscripts of recent developments in important areas related to pharmaceutical design within a therapeutic field. They could include accounts of the author’s research work combined with a review of the recent literature so that the readers will not only have the opportunity of benefiting from the author’s contribution, but will also gain access to a broader perspective of the field.

We will need to have about 250-300 printed pages in the journal issue from about 10-15 authors who are leading experts in the field (for manuscript preparation details please visit Author Guidelines Please note that no research articles will be accepted as a part of the thematic issue.

As the Executive Guest Editor, you will be required to contribute a one-page foreword highlighting the importance of the chosen topic and of the articles contained in the issue. You may also contribute an article to the issue yourself. You will be entitled to free online subscription to the whole volume of the journal for the year in which your issue has appeared. Appointment as the Executive Guest Editor is renewable by mutual agreement.

I would be grateful if you could please send your reply to me at thematicissue@benthamscience.org. as soon as possible along with the choice of the proposed theme/ topic area of your interest.

I shall be looking forward to receiving your positive reply.

Yours truly,

Prof. William A. Banks
Editor-in-Chief Current Pharmaceutical Design
Email: thematicissue@benthamscience.org.

                                                                                                                                                                               

Stem-Cell Gene Therapy Restores Immune System Response

Researchers found that after testing five SCID-X1 patients who received both gene therapy and low-dose chemotherapy, four of the patients showed improvements in immune function. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) have come up with a new gene therapy that can restore immunity…

The standard treatment would include a transplant of stem cells, which can be obtained from the direct family members. Only one of them unfortunately perished, due to a pre-existing condition that damaged their lungs before the new therapy could be applied. Currently, patients suffering from SCID-X1 are treated with stem cell transplants.

The National Institute of Allergy and Infectious Diseases reports a procedure including the extraction, genetic correction and reinsertion of a patient’s bone marrow can help their immune systems improve over time.

SCID-X1 is generally triggered by mutations in the IL2RG gene that averts infection-fighting immune cells from developing and working normally, leaving inflicted children highly vulnerable to life-threatening infections. One of the lifesaving treatments for very young children with SCID-X1 is transplantation of stem cells, ideally from a sibling donor who is genetically matched.

In the latest study, scientists examined the safety and effectiveness of gene therapy pooled with low-dose chemotherapy in five SCID-X1 patients.

Using a lentiviral vector, the scientists included a healthy IL2RG gene in the stem cells. The patients were then given low-dose chemotherapy to eliminate the defective blood cells. One patient received treatment three years ago with continued improvements. Another patient is doing well and continues to show improvement even after three years of the gene therapy. Three more patients aged 7 to 24 are improving, though it has only been three to six months since the treatment was performed. All surviving patients are continually being monitored.

Severe Combined Immunodeficiency is a rare immunodeficiency that leads to frequent serious infections. They manipulated the virus gene to deliver the right gene to the cell. By collecting an individual s stem cells and modifying them with a lentivirus, the gene-corrected cells can be returned into the blood to help produce normal healthy immune cells. Accessible treatments for this once-deadly disorder have centered around bone marrow transplants, yet encouraging results have been reported by an on-going clinical trial for an emerging gene therapy – Lentiviral gene transfer.

To determine the safety and effectiveness of lentiviral gene transfer as a treatment for children and adolescents with X-linked severe combined immunodeficiency.

Resource : http://goo.gl/nUrAFf

Autism Tree Project Foundation Nov 2015

GIOSTAR CEO at Autism Tree Project Foundation Event Nov 2015

 

 

Autism Tree Project Foundation was honored to host our Inaugural Neuroscience Conference at the Sanford Consortium for Regenerative Medicine on Thursday, November 5, 2015. This one-day conference was a collaborative effort in conjunction with Autism Tree Project Foundation.

Giostar Honored With Asian Heritage Award for Best in Business Category

Giostar Honored With Asian Heritage Award for Best in Business Category

Giostar Honored With Asian Heritage Award for Best in Business Category

DR. ANAND SRIVASTAVA AND DEVEN PATEL

Dr. Anand Srivastava and Deven Patel are co-founders of GIOSTAR (Global Institute of Stem Cell Therapy and Research), a leading stem cell therapy and research institute headquartered in San Diego. The company was founded to aid those suffering from debilitating health conditions such as Parkinson’s, Alzheimer’s, stroke, spinal cord injuries, cancer and diabetes. The company’s Regenerative Medicine program provides promise for treatments of diseases previously regarded as incurable.

Dr. Srivastava is regarded as a pioneer in the research of stem cell therapy and has long been associated with major academic and scientific institutions, including UCSD, UCLA and the Salk Research Institute. His work also extends to the research of cancer and gene therapy.

Recently, GIOSTAR Chairman Dr. Srivastava was invited to chair the session at the 8th Annual World Congress of Regenerative Medicine & Stem Cell-Korea. He has been
a frequent guest on numerous international conferences as the keynote speaker, presenter and on panels of experts. The speakers under his Chairmanship for this conference are the Who’s Who in the field of Stem Cell Science from the top universities around the world such as Cambridge and Oxford.

Mr. Patel’s role has been to take Dr. Srivastava’s research and create cell transplant programs with several state governments in India and to launch collaborative efforts with several other countries to establish treatment centers. Under his leadership, GIOSTAR has dedicated a state-of-the-art stem cell treatment hospital in Ahmedabad, India, and is planning additional facilities in China, Thailand, Dubai, the Philippines, Brazil, Sweden, Turkey and the Bahamas.

At GIOSTAR, Mr. Patel is in charge of developing stem cell transplant program for four different State Governments in India with total population of close to155 million. The four State Governments in Indi are preparing to treat their large, poor populations suffering from sickle cell anemia and thalassemia. GIOSTAR is in negotiations with China’s public and private sector to start stem cell transplant program at ten different locations.

Mr. Patel has served as the founding President of Asian and Pacific American Coalition (APAC), representing San Diego API communities from nine Asian countries and spearheaded its efforts in 2011 at City Hall to create the new 9th City Council District in City of San Diego to be an Asian Pacific American influenced district through the restricting process.

 

Source : http://goo.gl/35I4Ek

Regenerative Medicine Adult Stem Cells: The Science Behind the Magic

Regenerative medicine products are built via a combination of three elements: living cells, a matrix to support the living cells (i.e. a scaffold), and cell communicators (or signaling systems) to stimulate the cells, and their surrounding environment to grow and develop into new tissue.

These are special cells in the body that can turn into other types of cells. During the healing process, regenerative cells are called to the area of the body that needs repair. Factors in the area influence the regenerative cells to become repair cells.

Interestingly, the same regenerative cells that repair bone can also repair muscle, tendon, ligament, or cartilage. Of all of the types of cells, regenerative cells have the greatest potential to promote healing.

Regenerative cells are undifferentiated cells found in bone marrow that have the capacity to become bone, muscle, cartilage, ligament and tendon cells. Upon arrival to the injured tissue, regenerative cells take on the characteristics of that host tissue.

Stem Cell

This naturally occurring process is the body’s way of initiating the healing cascade. Because of the dramatic healing capabilities of regenerative cells, BioCellular Therapies has developed concise research and methods that will deliver an increased number of these cells, millions versus thousands, to injured tissue, thereby enhancing the healing process.

Isolating Adult Stem Cells

Using the body’s natural T- Cells for the tissue regenerative property which is highly concentrated in bone marrow. Isolating adult stem cells from a variety of tissues in addition to the blood allows for the ability to create a systematic approach, and specifically crafted treatment plan created specific to each patient.

It is understood that no two people are the same. Hence why we take the time to research and find out every detail of each patient. With our state of the art technology, and research we strive to create the best treatment plan. Upon countless hours of research our doctors do an in depth patient history, and develop the best plan possible for you.

Understanding Adult Stem Cells

ASC stands for adult stem cell. The adult stem cell can renew itself and can differentiate to yield some or all of the major specialized cell types of the tissue or organ. The primary roles of adult stem cells in a living organism are to maintain and repair the tissue in which they are found. This is only found in adults.

Where Are ASCS?

Adult stem cells have been found in the brain, bone marrow, blood vessels, skeletal muscle, and other organs and tissues. They are in specific areas of each tissue, where they may remain dormant for years, dividing and creating new cells only when they are activated by tissue injury, disease or anything else that makes the body need more cells.

How Do We Get ASCS

Adult stem cells can be isolated from the body in different ways, depending on the tissue. Mesenchymal stem cells, which can make bone, cartilage, fat, fibrous connective tissue, and cells that support the formation of blood can also be isolated from bone marrow. Which is considered to be he most nutrient in the body of ASCs.

Focus Is On Cures

Regenerative medicine includes tissue engineering but also incorporates research on self-healing – where the body uses its own systems, sometimes with help foreign biological material to recreate cells and rebuild tissues and organs. The focus is on cures instead of treatments for complex, often chronic, diseases.

Source : http://goo.gl/by4YRS

STEPHEN HAWKING MET WITH MR. DEVEN PATEL

Giostar - Stem Cell Therapy

Stephen Hawking met with Mr. Deven Patel the CEO of San Diego based Global Institute of Stem Cell Therapy and Research (GIOSTAR) on Saturday to learn more about how soon stem cell research can help in his neurological disorder ALS (amyotrophic lateral sclerosis) that has left the famed British physicist completely paralyzed.

He was visiting San Diego to attend the private tree planting ceremony in memory of one of his oldest friends, the late San Diego philanthropist Dennis Avery.

Giostar CEO Mr. Deven Patel with Mr. Stephen Hawking

Giostar CEO Mr. Deven Patel with Mr. Stephen Hawking

Dr. Hawking spent more than hour with Mr. Patel in private meeting to learn the recent development in the field of stem cells, specially related to ALS, the condition British Physicist was diagnosed for almost five decades ago. “Even after his long afternoon event, he was very attentive to my stem cell presentation,” said Mr. Patel.

He had so many questions in his mind and he was very encouraged with the progress of the stem cell science in the field of neurology. Mr. Patel has requested his staff for his medical history to be studied by GIOSTAR team of scientists and clinicians.

With the advancement of stem cell science, our range of interests at GIOSTAR is expanding every single day. While our therapeutic programs are focused exclusively on the transplantation of tissue-derived (adult) stem cells and progenitor cells for several degenerative diseases of different organs, we believe there is a utility in all types of stem cells and their progeny.

Today GIOSTAR scientists study all three types of stem cells: tissue-derived stem cells, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, as well as progenitor cells. Molecular biology, genetic engineering and protein chemistry are core technologies for conducting this research. We consider all of these cell types as viable options both as cell-based therapies and as tools and technologies for drug discovery and development.

To speed up the transition from research to treatment, GIOSTAR has collaborated with the government of India to bring its treatment for sickle cell anemia to three states in the country serving some 150 million people in the world’s largest stem cell treatment hospital setting of its kind! In 2011 GIOSTAR has also inaugurated one of the world’s first dedicated stem cell treatment hospital in Ahmedabad, India. The company is developing plans for similar facilities in California as well as China, Thailand, Philippines, Dubai, Brazil, Sweden, Bahamas and few more worldwide locations.

The Chairman of GIOSTAR Dr. Anand Srivastava said, with the rapid progress in the field of stem cell science, we are not that far from the cures for many devastating diseases that are considered incurable today. “And If we can cure great human being like Dr. Stephen Hawking, this world certainly will be a better place to live,” he said.

Giostar - Stem Cell Therapy

Make An Inquiry

We are here to help you

Click Here

Copyright © 2021, GIOSTAR. All rights reserved.

WordPress Video Lightbox